Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 3Lung Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 4pembrolizumab 3Trastuzumab 3Sunitinib 3Nivolumab 3ulixertinib 2tipifarnib 2palbociclib 2lenvatinib 2belinostat 2Specimen Handling 2Sirolimus 2Radiosurgery 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × IT-101 × Genitourinary × Clear all
NCT00333502 2020-05-28

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Lumos Pharma

Phase 1/2 Completed
62 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Skin Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡